

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Apixaban for the prevention of venous thromboembolism in people undergoing elective knee and hip replacement surgery

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

No equality issues were raised during draft scope consultation. Consultees raised the issue of providing non-injectable medications for people with needle phobia. Dabigatran and rivaroxaban (both oral agents) are currently recommended by NICE as options for prevention of VTE in elective knee and hip surgery.

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

These issues are not relevant to be discussed by the Appraisal Committee
--

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No changes were made to the draft scope regarding equality issues.
--

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): ...Janet Robertson...

Date: 18 February 2011